Molecular Medicine |
From the Department of Biomedical Sciences, Division of Biochemistry, Laboratory of Cardiovascular Research, University of Sassari, Sassari, Italy, and National Laboratory of the National Institute of Biostructures and Biosystems, Osilo, Italy.
Correspondence to Carlo Ventura, MD, PhD, Department of Biomedical Sciences, Division of Biochemistry, University of Sassari, Viale San Pietro 43/B, 07100 Sassari, Italy. E-mail chim_med{at}ssmain.uniss.it
| Abstract |
|---|
|
|
|---|
-myosin heavy chain and myosin light chain-2V
transcripts, two markers of cardiac differentiation. Moreover,
dynorphin Bexposed cells were positively stained in the presence of
MF 20, a mouse monoclonal antibody raised against the
-myosin heavy
chain. Opioid receptor antagonism and inhibition of opioid gene
expression by a prodynorphin antisense phosphorothioate
oligonucleotide blocked DMSO-induced cardiogenesis,
suggesting an autocrine role of an opioid gene in developmental
decisions.
Key Words: opioid gene expression myocardial development transcription factors stem cells
| Introduction |
|---|
|
|
|---|
-myosin heavy chain (MHC), cardiac troponin C, and atrial
natriuretic peptide.6 The availability of
pluripotent embryonal stem (ES) cells now provides a valuable tool for
the molecular dissection of developmental events. P19 is a line of
pluripotent murine ES cells that can be differentiated into multiple
cell types by cellular aggregation in the presence of differentiating
agents and emulates the molecular and morphological events occurring
during early embryonic development.7 P19 cells treated
with retinoic acid differentiate into various neuroectodermal
derivatives, whereas cells aggregated in the presence of DMSO
differentiate into cardiac and skeletal muscle along with other
mesodermal and endodermal cell types.7 The resulting
cardiomyocytes have been found to be embryonic in nature
and express both GATA-4 and Nkx-2.5 genes.8 In P19 cells,
inhibition of GATA-4 expression blocked DMSO-induced
cardiogenesis,9 whereas transfection of the Nkx-2.5 gene
led to the appearance of a myocardial lineage in the absence of
DMSO.8 These findings indicate that the establishment of a
cardiac phenotype proceeds with similar molecular patterning in
P19 cells and in the in vivo environment and suggest that these cells
should be considered as an in vitro model recapitulating the molecular
plight that is impacting the process of cardiogenesis in the developing
embryo. The identification of intracellular growth regulators capable
of priming cardiogenesis is now a crucial issue. Increasing
experimental evidence indicates that the myocardial cell may act as a
source for peptides, playing a crucial role in signal transduction
mechanisms. We have shown that cardiac myocytes express the
prodynorphin gene and are able to synthesize and secrete dynorphin
B,10 a natural
-opioid receptor agonist. Stimulation of
these receptors modified both cytosolic Ca2+ and
pH homeostasis and remarkably affected myocardial
contractility.11 12 It is now established
that opioid peptides can also act as growth regulators in a wide
variety of normal and malignant tissues.13 14 15 In our
previous investigations, prodynorphin gene and dynorphin B expression
were enhanced in myocytes isolated from BIO 14.6 Syrian
hamsters,16 an experimental model of hereditary
cardiomyopathy exhibiting remarkable changes in
myocyte architecture, growth, and differentiation. In this model, the
overexpression of the prodynorphin gene was related to both the
activation of nuclear embedded isozymes of protein kinase C (PKC) and
cytosolic Ca2+ overload,16 17
suggesting the recruitment of crucial signaling pathways.
Interestingly, in cardiomyopathic myocytes, secreted
dynorphin B elicited a tonic feed-forward stimulation of its coding
gene.18 Moreover, recently uncovered nuclear opioid
receptors were found to be coupled to the activation of both nuclear
PKC activity and prodynorphin gene transcription.19 These
findings suggest that an opioid gene may play an autocrine and
intracrine role in the regulation of myocardial homeostasis. In the present study, we used P19 ES cells to examine prodynorphin gene transcription and dynorphin B expression throughout different stages of DMSO-induced cardiac differentiation. In this in vitro model, we also aimed to elucidate whether the expression of a cardiogenic program may be triggered by the exposure of P19 cells to dynorphin B in the absence of DMSO. A potential role of the prodynorphin gene and endogenous dynorphin B in cardiogenesis was explored.
| Materials and Methods |
|---|
|
|
|---|
Reverse TranscriptionPolymerase Chain Reaction (RT-PCR)
Total RNA was extracted at the indicated time and reverse
transcribed. The resulting cDNA was then amplified according to the
reaction conditions previously reported.20 Using 35 PCR
cycles, the products of the investigated genes were all within the
linear phase of the reaction. Specific primers for MHC, myosin light
chain-2V (MLC), GATA-4, Nkx-2.5, and GAPDH are described elsewhere (see
expanded Materials and Methods online, available at
http://www.circresaha.org). Specific primer pairs against mouse
prodynorphin gene were 5'-CTGCTGACCGGATGAATGATGAA-3' and
5'-GCAGCGGAACAAGCACAAGAGGAT-3'. PCR conditions were 94°C for 30
seconds, 59°C for 30 seconds, and 72°C for 1 minute.
Analysis of Prodynorphin Gene Expression
Prodynorphin mRNA was also assessed by solution hybridization
RNase protection.13 20 Briefly, a 424-bp fragment of the
main exon of mouse genomic prodynorphin clone was inserted into
pCRII-TOPO (Invitrogen). Transcription of the plasmid linearized with
ApaI generated a sense strand of prodynorphin mRNA used to
construct a standard curve of prodynorphin mRNA, whereas transcription
of the plasmid linearized with BamHI in the presence of
[32P]CTP (800 Ci/mmol) gave an antisense strand
used to hybridize cellular prodynorphin mRNA.
Nuclear runoff transcription assay was performed in isolated nuclei, as described.16 Nuclear RNA was subjected to RNase protection assay. 32P-labeled RNA was hybridized for 12 hours at 55°C with unlabeled antisense prodynorphin mRNA synthesized, as described above. 32P-labeled nuclear RNA was also hybridized with unlabeled antisense cyclophilin mRNA, used as a constant mRNA for control. Immunoreactive dynorphin B was measured by a previously described radioimmunoassay procedure.10 16
Transfections
Undifferentiated P19 cells were transfected with 200 nmol/L
prodynorphin antisense phosphorothioate oligonucleotide
or 200 nmol/L scrambled phosphorothioate oligomer (negative control)
(Sequitur Inc) with the aid of cationic lipids (Oligofectins) provided
by the manufacturer. Transfection was carried out for 4 hours at 37°C
in a serum-free medium. Cells were then replaced in a serum-containing
medium and, after a 24-hour period, were exposed to 1% DMSO. The
transfection procedure was repeated at 48-hour intervals. A
fluorescein-labeled derivative of the antisense
oligonucleotide was used to determine transfection
efficiency. Fluorescence microscopy performed at defined times
after transfection revealed that
90% of identifiable nuclei had
taken up the fluorescent oligonucleotide and
that nuclear staining persisted for the duration of the experiment (not
shown). After 4 days of DMSO treatment, cells were fixed with 4%
paraformaldehyde and MHC was identified by the MF 20
mouse antimyosin monoclonal antibody.21
An expanded Materials and Methods section is available online at http://www.circresaha.org.
| Results |
|---|
|
|
|---|
|
In this study, we examined whether the increase in GATA-4 and Nkx-2.5
gene expression elicited by DMSO may be associated with the expression
of an endogenous growth regulator in the early phase of the
cardiac commitment of P19 cells. Figure 2
shows that the prodynorphin gene was expressed under basal conditions
in cells cultured without DMSO. RT-PCR suggested a substantial increase
in prodynorphin mRNA after cell exposure to DMSO (Figure 2A
).
Such an effect was additionally confirmed by RNase protection
experiments revealing that prodynorphin gene expression was already
enhanced after 2 days in the presence of DMSO and reached a maximum
after 4 days of treatment. In vitro runoff assays performed in nuclei
isolated from P19 cells indicated that the DMSO effect occurred at the
transcriptional level (Figure 2C
).
|
Consistent amounts of dynorphin B were detected in P19 cells
and their incubation media (Figure 2D
). Confirming our previous
observations in myocardial cells,10 16 the intracellular
levels of dynorphin B were significantly lower than the levels detected
in the incubation medium, suggesting that in the P19 cell
prodynorphin-derived peptides may be constitutively released soon after
synthesis. The levels of both intracellular and secreted dynorphin B
were significantly increased in DMSO-treated P19 cells compared with
unexposed cells. The rise in dynorphin B expression was already evident
after 2 days of treatment and peaked after 4 days of exposure (Figure
2D).
The finding that DMSO-triggered induction of cardiogenic genes was
preceded by the activation of prodynorphin gene and dynorphin B
expression suggests that an opioid gene may be a suitable candidate for
the initiation of a cardiac program of differentiation. In the absence
of DMSO, 1 µmol/L dynorphin B was able to induce the expression
of Nkx-2.5 and GATA-4 genes after 1 or 2 days of treatment,
respectively (Figure 3
). Exposure to
dynorphin B also enhanced MHC and MLC gene expression (Figure
3). The dose-response curve of the effect of dynorphin B on
Nkx-2.5 and GATA-4 mRNA expression revealed that the opioid peptide was
effective at a concentration as low as
10-8 mol/L (Figure
3). Figure 3
shows that the opioid effect was specific in
nature, because it was abolished by Mr-1452, a selective
-opioid
receptor antagonist.19 MHC expression was
additionally assessed in immunofluorescence studies
with the aid of the mouse MF 20 monoclonal antibody. Whereas MF
20positive cells were not detectable in the absence of both DMSO and
dynorphin B (Figure 4A
), MF 20 labeling
was clearly observed in DMSO-treated cells (Figure 4B
). Positive
staining was also observed in P19 cells exposed to dynorphin B in the
absence of DMSO (Figure 4C
). The pattern of MF 20 staining in
dynorphin Btreated cells was superimposable to that observed in cells
exposed to DMSO, providing additional evidence for the involvement of
dynorphin B in the activation of a cardiogenic program.
|
|
The cardiogenic effect of an exogenously administered opioid agonist
prompted us to investigate whether an intrinsically produced opioid
peptide may elicit cardiogenesis through an autocrine mechanism. For
this purpose, cell aggregation with DMSO, a treatment enhancing the
synthesis and secretion of dynorphin B, was performed in the presence
of an opioid receptor antagonist. Figure 5
shows that Mr-1452 downregulated
DMSO-induced GATA-4 and Nkx-2.5 mRNA expression as well as
DMSO-elicited activation of MHC and MLC genes. Specificity of the
antagonistic effect of Mr-1452 was inferred by the finding
that the inactive enantiomer Mr-1453 failed to abolish the DMSO action
(Figure 5
). We next assessed MHC expression in P19 cells
transfected with a prodynorphin antisense phosphorothioate
oligonucleotide. In cells primed for 4 days with 1%
DMSO, transfection resulted in an 80% to 90% decrease in both
intracellular and secreted dynorphin B compared with nontransfected
DMSO-treated cells (Figure 6
). The
immunofluorescence analysis of MF 20
staining revealed that P19 prodynorphin antisense transfectants failed
to develop in MHC-positive cells in response to DMSO (Figure 7
). The treatment of P19 cells with
Mr-1452 was also able to prevent the appearance of MF 20 staining in
DMSO-exposed cells (Figure 7
).
|
|
|
| Discussion |
|---|
|
|
|---|
-opioid receptor antagonist suppressed the DMSO
effect on cardiogenic and cardiac-specific genes prompts the hypothesis
that cardiogenesis may be controlled by an opioid generelated
autocrine environment. Such a hypothesis is substantiated by the
observation that both antisense-mediated downregulation of the
prodynorphin gene and opioid receptor antagonism counteracted MHC
expression. Previous studies22 23 have established that both Nkx-2.5 and GATA-4 can be induced in mesoderm-originated precardiac cells by endoderm-derived signals comprising several members of bone morphogenetic proteins (BMPs) belonging to the transforming growth factor-ß superfamily. It is now evident that both BMP receptors and DMSO convey differentiating stimuli to the nuclear transcriptional machinery through common signal transduction pathways that involve the activation of mitogen-activated protein kinases (MAPKs).24 25 DMSO also elicits intracellular Ca2+ overload and phosphoinositide turnover, thereby increasing the cellular availability of diacylglycerol and the activity of PKC isozymes.26 27 Interestingly, opioid receptor stimulation is coupled to the activation of both PKC-16 28 29 and MAPK-mediated pathways30 and has also been shown to affect phosphoinositide turnover,12 31 promoting the release of Ca2+ from an intracellular storage site.10 11 12 18 In addition, an upstream initiator-like sequence in the promoter of the prodynorphin gene has been shown to be recognized by a DNA-binding protein acting as a tyrosine kinase substrate.32 Hence, opioid-related signaling shares crucial developmental pathways with both BMP- and DMSO-activated cascades. Opioid peptides have also been shown to be nuclear proteins responsive to growth arrest and differentiation signals.33 In this regard, the opioid peptide precursor preprodynorphin has been found to display structure similarity with the helix-loop-helix motif of multiple DNA-binding proteins and to exhibit cysteine-rich regions characteristic of zinc-finger domains.34 Moreover, dynorphin B proved to be a specific ligand of nuclear opioid receptors in myocardial cells.19 These receptors were overexpressed in nuclei of myocytes isolated from Syrian cardiomyopathic hamsters and coupled to nuclear PKC activation and prodynorphin gene transcription, suggesting that intracrine signals for growth regulation may be fashioned by an opioid gene.
The possibility that the prodynorphin gene may be involved in the orchestration of cardiogenesis may be of particular biological relevance. The attempt at rescuing the cardiac function in damaged myocardium is now an area of inquiry.35 Damaged skeletal muscle is able to regenerate because of the presence of satellite cells, which are undifferentiated myoblasts.36 In contrast, destruction of cardiac myocytes is associated with an irreversible loss of myocardium and replacement with scar tissue, because it lacks stem cells.36 Growing evidence indicates that stem cells obtained from skeletal muscle can be implanted into injured myocardium and are able to differentiate into cardiac muscle fibers,37 thereby providing a unique opportunity to repair damaged heart muscle. Strikingly, besides showing clear morphological evidence of a cardiac phenotype, the implanted cells exhibited long-term survival within the context of recipient myocardium.38 These findings are consistent with the hypothesis of milieu-influenced differentiation of the implanted stem cells into cardiac-like muscle cells. In previous investigations, we have shown that as a result of prodynorphin gene expression, dynorphin B is both synthesized and secreted from adult myocytes.10 16 17 18 In this study, we show that this opioid peptide is also secreted by an ES cell and may act in an autocrine fashion to elicit the appearance of a cardiac phenotype. Therefore, cardiac myocytes within the recipient myocardium and implanted stem cells might both generate a cardiogenic program involving the expression of an opioid gene and that of its related peptide product. In addition, dynorphin B itself has previously been shown to enhance prodynorphin gene expression in adult myocytes,18 19 suggesting that the local availability of dynorphin B may be enhanced by a paracrine crosstalk among myocytes and transplanted stem cells.
It is becoming evident that ES cells can be differentiated in vitro and used as a novel source of cells for transplantation.38 The results of the present study provide evidence that formation of a myocardial cell can be triggered in vitro by an opioid gene. Additional studies are needed to verify whether manipulation of the prodynorphin gene may prove effective in triggering cardiac differentiation in human stem cells implanted within an in vivo environment. Clarification of this issue must await more direct functional studies and may pave the way for developmental approaches to tissue engineering and myocardial regeneration.
| Acknowledgments |
|---|
Received May 3, 2000; accepted June 27, 2000.
| References |
|---|
|
|
|---|
-Opioid peptide receptor stimulation increases cytosolic pH and
myofilament responsiveness to Ca2+ in cardiac
myocytes. Am J Physiol. 1991;261:H1671H1674.
and
Opioid receptor stimulation affects
cardiac myocyte function and Ca2+ release from an
intracellular pool in myocytes and neurons. Circ Res. 1992;70:6681.
and -
genes. FEBS Lett. 1999;449:135140.[Medline]
[Order article via Infotrieve]
in chicken embryo neuron
cultures. Proc Natl Acad Sci U S A. 1993;90:29152919.
subunits. J Neurochem. 1998;70:635645.[Medline]
[Order article via Infotrieve]
-adrenergic and
-opioidergic mediated
inositol(1,4,5)P3/inositol(1,3,4,5)P4
formation in adult cultured rat ventricular
cardiomyocytes. Biochem Biophys Res Commun. 1991;179:972978.[Medline]
[Order article via Infotrieve]
This article has been cited by other articles:
![]() |
R. N. Re and J. L. Cook The physiological basis of intracrine stem cell regulation Am J Physiol Heart Circ Physiol, August 1, 2008; 295(2): H447 - H453. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Cadet, K. J. Mantione, W. Zhu, R. M. Kream, M. Sheehan, and G. B. Stefano A Functionally Coupled {micro}3-Like Opiate Receptor/Nitric Oxide Regulatory Pathway in Human Multi-Lineage Progenitor Cells J. Immunol., November 1, 2007; 179(9): 5839 - 5844. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Oyama, T. Nagai, H. Wada, A. T. Naito, K. Matsuura, K. Iwanaga, T. Takahashi, M. Goto, Y. Mikami, N. Yasuda, et al. Cardiac side population cells have a potential to migrate and differentiate into cardiomyocytes in vitro and in vivo J. Cell Biol., January 29, 2007; 176(3): 329 - 341. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Kim, A. L. Clark, A. Kiss, J. W. Hahn, R. Wesselschmidt, C. J. Coscia, and M. M. Belcheva {micro}- and {kappa}-Opioids Induce the Differentiation of Embryonic Stem Cells to Neural Progenitors J. Biol. Chem., November 3, 2006; 281(44): 33749 - 33760. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Ding, C.-j. Liu, Y. Huang, R. P. Hickey, J. Yu, W. Kong, and P. Lengyel p204 Is Required for the Differentiation of P19 Murine Embryonal Carcinoma Cells to Beating Cardiac Myocytes: ITS EXPRESSION IS ACTIVATED BY THE CARDIAC GATA4, NKX2.5, AND TBX5 PROTEINS J. Biol. Chem., May 26, 2006; 281(21): 14882 - 14892. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Fukuda and S. Yuasa Stem Cells as a Source of Regenerative Cardiomyocytes Circ. Res., April 28, 2006; 98(8): 1002 - 1013. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Hakuno, T. Takahashi, J. Lammerding, and R. T. Lee Focal Adhesion Kinase Signaling Regulates Cardiogenesis of Embryonic Stem Cells J. Biol. Chem., November 25, 2005; 280(47): 39534 - 39544. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Ventura CAM and Cell Fate Targeting: Molecular and Energetic Insights into Cell Growth and Differentiation Evid. Based Complement. Altern. Med., September 1, 2005; 2(3): 277 - 283. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Pepe, O. W.V van den Brink, E. G Lakatta, and R.-P. Xiao Cross-talk of opioid peptide receptor and {beta}-adrenergic receptor signalling in the heart Cardiovasc Res, August 15, 2004; 63(3): 414 - 422. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Ventura, M. Maioli, Y. Asara, D. Santoni, I. Scarlata, S. Cantoni, and A. Perbellini Butyric and Retinoic Mixed Ester of Hyaluronan: A NOVEL DIFFERENTIATING GLYCOCONJUGATE AFFORDING A HIGH THROUGHPUT OF CARDIOGENESIS IN EMBRYONIC STEM CELLS J. Biol. Chem., May 28, 2004; 279(22): 23574 - 23579. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. C. Heng, H. K. Haider, E. K.-W. Sim, T. Cao, and S. C. Ng Strategies for directing the differentiation of stem cells into the cardiomyogenic lineage in vitro Cardiovasc Res, April 1, 2004; 62(1): 34 - 42. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. Solloway and R. P. Harvey Molecular pathways in myocardial development: a stem cell perspective Cardiovasc Res, May 1, 2003; 58(2): 264 - 277. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Sachinidis, B. K. Fleischmann, E. Kolossov, M. Wartenberg, H. Sauer, and J. Hescheler Cardiac specific differentiation of mouse embryonic stem cells Cardiovasc Res, May 1, 2003; 58(2): 278 - 291. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Ventura, E. Zinellu, E. Maninchedda, M. Fadda, and M. Maioli Protein Kinase C Signaling Transduces Endorphin-Primed Cardiogenesis in GTR1 Embryonic Stem Cells Circ. Res., April 4, 2003; 92(6): 617 - 622. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Ventura, E. Zinellu, E. Maninchedda, and M. Maioli Dynorphin B Is an Agonist of Nuclear Opioid Receptors Coupling Nuclear Protein Kinase C Activation to the Transcription of Cardiogenic Genes in GTR1 Embryonic Stem Cells Circ. Res., April 4, 2003; 92(6): 623 - 629. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||